Paper41301700
Drug Repurposing for AML: Structure-Based Virtual Screening and Molecular Simulations of FDA-Approved Compounds with Polypharmacological Potential.
Abdelsayed M and 1 other. Biomedicines, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Drug Repurposing for AML: Structure-Based Virtual Screening and Molecular Simulations of FDA-Approved Compounds with Polypharmacological Potential. Papers, record 41301700. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41301700
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Drug Repurposing for AML: Structure-Based Virtual Screening and Molecular Simulations of FDA-Approved Compounds with Polypharmacological Potential.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40233673 | Computational screening of natural products as tryptophan 2,3-dioxygenase inhibitors: Insights from CNN-based QSAR, molecular docking, ADMET, and molecular dynamics simulations. | Comput Biol Med | 2025 | https://conductscience.org/library/papers/40233673 | PubMed |
| 2 | 37655965 | Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function. | Cancer Discov | 2023 | https://conductscience.org/library/papers/37655965 | PubMed |
| 3 | 33054125 | Differentiation therapy of myeloid leukemia: four decades of development. | Haematologica | 2021 | https://conductscience.org/library/papers/33054125 | PubMed |
| 4 | 40725243 | AI-Driven Polypharmacology in Small-Molecule Drug Discovery. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40725243 | PubMed |
| 5 | 36892565 | Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax. | Cancer Discov | 2023 | https://conductscience.org/library/papers/36892565 | PubMed |
| 6 | 39406957 | Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia. | Curr Treat Options Oncol | 2024 | https://conductscience.org/library/papers/39406957 | PubMed |
| 7 | 37462852 | Probing the molecular mechanisms of α-synuclein inhibitors unveils promising natural candidates through machine-learning QSAR, pharmacophore modeling, and molecular dynamics simulations. | Mol Divers | 2024 | https://conductscience.org/library/papers/37462852 | PubMed |
| 8 | 29238707 | Drug Repurposing for the Treatment of Acute Myeloid Leukemia. | Front Med (Lausanne) | 2017 | https://conductscience.org/library/papers/29238707 | PubMed |
| 9 | 33034194 | Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). | J Med Chem | 2020 | https://conductscience.org/library/papers/33034194 | PubMed |
| 10 | 21541964 | SwissParam: a fast force field generation tool for small organic molecules. | J Comput Chem | 2011 | https://conductscience.org/library/papers/21541964 | PubMed |
| 11 | 25558886 | DataWarrior: an open-source program for chemistry aware data visualization and analysis. | J Chem Inf Model | 2015 | https://conductscience.org/library/papers/25558886 | PubMed |
| 12 | 17004707 | A critical assessment of docking programs and scoring functions. | J Med Chem | 2006 | https://conductscience.org/library/papers/17004707 | PubMed |
| 13 | 34265047 | Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. | Blood | 2021 | https://conductscience.org/library/papers/34265047 | PubMed |
| 14 | 28124097 | Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. | Acta Neuropathol | 2017 | https://conductscience.org/library/papers/28124097 | PubMed |
| 15 | 32780180 | In silico screening of GABA aminotransferase inhibitors from the constituents of Valeriana officinalis by molecular docking and molecular dynamics simulation study. | J Mol Model | 2020 | https://conductscience.org/library/papers/32780180 | PubMed |
| 16 | 36976323 | Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. | Mol Cancer Res | 2023 | https://conductscience.org/library/papers/36976323 | PubMed |
| 17 | 32726718 | Molecular dynamics simulation, free energy landscape and binding free energy computations in exploration the anti-invasive activity of amygdalin against metastasis. | Comput Methods Programs Biomed | 2020 | https://conductscience.org/library/papers/32726718 | PubMed |
| 18 | 25599133 | Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. | Nat Med | 2015 | https://conductscience.org/library/papers/25599133 | PubMed |
| 19 | 40240608 | Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. | Nature | 2025 | https://conductscience.org/library/papers/40240608 | PubMed |
| 20 | 16381872 | The RCSB PDB information portal for structural genomics. | Nucleic Acids Res | 2006 | https://conductscience.org/library/papers/16381872 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42512057 | Risk Recognition and Phenotyping in Cardiac and Vascular Diseases. | Biomedicines | 2026 | https://conductscience.org/library/papers/42512057 | PubMed |
| 42357359 | Interpreting the Black Box: Interpretable Machine Learning and Systems Pharmacology in Small-Molecule Therapeutics. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42357359 | PubMed |
| 41976180 | An In Silico and In Vitro Approach Identified Potential Trypanothione Synthetase Inhibitors with Trypanocidal Activity. | Molecules | 2026 | https://conductscience.org/library/papers/41976180 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| KDM1A | 23028 | PubTator's text mining | https://conductscience.org/library/genes/23028 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41301700
GET https://conductscience.org/api/papers/v1/41301700/references?page=2